Application of aloperine in the preparation of drugs for treating myocardial hypertrophy

A technology for myocardial hypertrophy and sophorine, which can be used in drug combinations, pharmaceutical formulations, cardiovascular system diseases, etc., and can solve problems such as decompensated myocardial hypertrophy and heart failure.
CN104887676BActive Publication Date: 2019-01-29NINGXIA MEDICAL UNIV
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Patents(China)
Current Assignee / Owner
NINGXIA MEDICAL UNIV
Publication Date
2019-01-29

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses application of aloperine serving as a drug for treating myocardial hypertrophy. Due to the fact that a rat myocardial hypertrophy model is established, the protecting effect and the mechanism of the aloperine on rat myocardial hypertrophy are explored and researched. An experiment result shows that when the aloperine is used within the safety dosage range, certain dosage-drug function relevance is shown when the dosage is 40 mg / kg, the heart weight, the left ventricle weight, the whole ventricle mass / the body mass and the left ventricle mass / the body mass can be remarkably improved, myocardial fibrosis is remarkably inhibited, cardiomyocyte hypertrophy and cardiomyocyte necrosis are reduced, myocardial compliance and the left ventricle diastole function are improved, myocardial contractility is improved, the serum NO concentration is improved, SOD activity and GSH-Px activity are improved, the ADMA level is reduced, the cTn-I content and the MDA content are reduced, the body oxidation resistance is improved, the lipid peroxidation level is reduced, and it is shown that the aloperine has the function of treating the myocardial hypertrophy.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the application of aloperine (Aloperine, ALO), in particular to the application of aloperine in the preparation of drugs for treating myocardial hypertrophy. Background technique

[0002] Cardiac hypertrophy is the adaptive response of the heart to adapt to various mechanical and neurohormonal stimuli. During the compensatory phase, the heart improves its pumping function by increasing the work output of the cardiomyocytes. But as the overload persists, this compensatory mechanism can develop into decompensated myocardial hypertrophy, leading to heart failure. The pathological changes of cardiac hypertrophy include the hypertrophy of cardiomyocytes and the proliferation and differentiation of fibroblasts, which are manifested as the increase of heart volume and mass.

[0003] Nitric oxide (NO) is a vasodilator factor synthesized and released by vascular endothelial cells. It is formed with L-arginine as a substrate an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More